UTI Natural Remedies

UTI Natural Remedies
Even though the matter can be debated either way, to disprove or prove, natural remedies can help prevent as well as get rid of urinary tract infection. Some physicians are of the opinion that antibiotics enhance the risk of UTI recurring as more and more bacteria get resistant to prevalent medication. It should be kept [...]

Even though the matter can be debated either way, to disprove or prove, natural remedies can help prevent as well as get rid of urinary tract infection.

Some physicians are of the opinion that antibiotics enhance the risk of UTI recurring as more and more bacteria get resistant to prevalent medication.

It should be kept in mind that changes in lifestyles and supportive measures are part and parcel of any naturopathy.

When talking of natural and alternative treatments in context of urinary tract infection cure and bladder infection treatment we have a healthy choice of choosing from the following options:

* Natural Remedies
* Homoeopathy
* Physical Medicines

The concentration of hydrogen-ion (commonly known as pH level) in the urinary tract defines how favorable the urine is for bacterial growth. On a scale of 0 to 14, a level of 7 is basic and neutral whereas a level of less that 7 is acidic.

Research and studies conducted to find the causes of bacterial growth point towards benefits of an alkaline pH in urine for preventing urinary tract infections and minerals, especially citrates, alkalize the urine. A steady dose of calcium or magnesium citrate supplements proves to be a great help in bladder infection treatment.

As infected urine that remains in the bladder during the night can cause irritation to the bladder, mineral supplements should be taken at bedtime for better effect.

Cranberry juice, by far the most renowned natural remedy, has been clinically proven to have antibacterial properties that restrict bacteria from adhering to the urethral tissue or bladder. Cranberry or blueberry juices in their pure form or at the most sweetened by apple or grape juice can disinfect the urinary tract to a great extent.

Homeopathic remedies should be taken after consulting a qualified consultant, as homeopathy is a holistic system of curing and medication depends upon the overall appearance, symptoms, and even behavioral attitudes of the patients.

Diabetic patients with UTI, however, should take homeopathic remedies only in water, as the sugar content of the lactose pellets can be detrimental to their sugar levels.

Cantharis, Apis mellifica, Staphysagria, and Sarsasparilla, are four of the most commonly used homeopathic remedies for different symptoms of UTI.

Physical medicines can provide temporary relief from certain acute symptoms such as pain. You can apply castor oil directly to the skin to soothe the irritation.

Another way in which you can get relief from pain is to cover a hot water bottle with cloth and apply it to the infected and painful area. This can ease pelvic pain along with cramping in the bladder.

You may choose any natural urinary tract infection cure but take care to keep consulting your physician or naturopath regularly so that progress and side effects, if any, can be monitored and addressed.

Treat UTIs Safely, Naturally and Effectively

UTI-Clear is a safe, proven, clinically developed herbal formula that clears and prevents bladder infections, cystitis, and UTI (urinary tract infections). UTI-Clear is a better solution than antibiotics which, over time, become less effective as you develop a tolerance for them.

Being natural, with no artificial preservatives, UTI-Clear is safe for adults and children, is non-addictive and has NO SIDE EFFECTS. It has become the formula of choice by thousands of satisfied customers around the world for treating and preventing cystitis, bladder and urinary tract infections.

UTI-Clear was developed by a Clinical Psychologist and is pharmaceutically manufactured to the highest standards.

Related articles

• Home Remedies For UTI
• Dealing with Recurrent Bladder infections naturally
• Cranberries Weaken UTI Bacteria’s Ability To Be Infectious

Free PDF Health Ebook...

Proven Roadmap to Banish Fears

� � Simply right click the ebook title above, and choose Save As to save to your desktop!� You can find more FREE Natural Health, Wellness and Pet Ebooks at Remedies4.com!

---

One in five kids may outgrow asthma

As many as one in five youngsters with asthma may grow out of the respiratory condition as they age, new research indicates. Continue reading...

Benefits of Juicing: Is Juicing Good For You?

With juice bars popping up in almost every city these days, juicing seems to be the new health nut go-to. People are trying out juice cleanses to shed pounds, detox, or just add a nutrient-packed snack to their diets. If you’re interested in trying out juicing or a juice cleanse, it’s important to understand the [...]

The post Benefits of Juicing: Is Juicing Good For You? appeared first on BuiltLean.com.

With juice bars popping up in almost every city these days, juicing seems to be the new health nut go-to. People are trying out juice cleanses to shed pounds, detox, or just add a nutrient-packed snack to their diets.

If you’re interested in trying out juicing or a juice cleanse, it’s important to understand the purpose of juicing, its benefits, and the best way for you to incorporate juice into your diet.

What Is Juicing?

In essence, juicing is extracting the juice from whole fruits and veggies. Some people may wonder why it has become so popular in the past few years, especially since we can simply purchase ready-made fruit and veggie juices at the store. The nutrients in the store-bought juices, however, are nowhere near the quantity or quality of those in fresh homemade juices made from whole (and if possible, organic) fruits and vegetables, because the nutrients in store-bought have been pasteurized. Juicing allows the preservation of the natural vitamins, minerals and enzymes of the raw produce.¹

It’s also a great way for people who are not big fans of fruits and veggies to get their recommended six to eight servings a day. For example, people who do not like beets can juice the beets together with fruits and berries, and receive the nutrients found in beets (potassium, iron, vitamin C), and enjoy at the same time.

Benefits of Juicing

Juicing allows pre-digestion, or the immediate absorption of all of the nutrients from produce. Plus, juicing provides versatility in vegetables because it helps people to enjoy more veggies they may not typically like to eat whole.

Juicing can aid in the digestive process and give it a little break, because it takes less energy to digest the produce as a liquid than as solid foods, which take many hours after consumption to deliver optimal nourishment to the body.²

It can also help in raising the pH balance in our bodies, and in turn, help to protect us from conditions related to acidic imbalances, including heart and kidney disease, osteoporosis, and diabetes.³

How to Juice In A Healthy Way

Most dietitians do not recommend a juicing-only weight loss plan because the lack of fiber and protein in juices often leaves us hungry, and at risk for losing too much muscle mass.⁴ However, a healthy way to juice for fat loss is to combine juicing with a balanced nutrition plan, because the body needs more than the nutrients fruits and vegetables provide.

Make sure to factor in the calories from the juice as a part of your overall diet. One ounce of juice usually contains about 15 calories. Also, the pulp leftover from juicing is actually where all of the healthy fiber is hiding, and it can be recycled into soups, rice dishes, pasta sauces, muffins, and even crackers (See: Juice Pulp Cracker Recipe). If you’re set on drinking your meal, combine the juice into a smoothie, by blending the pulp, nut butter or avocado for healthy fats, and Greek yogurt for protein.⁵

Popular Juicers and Juice Recipes⁶

Amazon.com’s top selling juicers range in price, starting at $49.99 for the Hamilton Beach Juice Extractor, jumping to $99.95 for the Breville Compact Juice Fountain, and reaching $299.00 for Breville Juice Fountain Elite. It is obviously important to find one that makes sense for your budget, but also be sure to pick a juicer with high voltage consumption and one with inner blades that are evenly spread out, to get the most juice from your fruits and veggies. Also, make sure to check and see if all of the juicer’s parts are break resistant and if replacement parts are available for purchase later.

When you’re ready, turn on your juicer and try out these tasty recipes:

Vegetable Juice Recipe

• Ingredients: 4 medium asparagus spears, 3 large carrots, and 2 large celery stalks.
• Directions: Process all ingredients in the juicer, shake, and serve.
• Nutrition Facts: 62 calories, 0.57 g fat, 9.65 g sugar, 3.01 g protein

Fruit Juice Recipe:

• Ingredients: 1 c blackberries, 1 kiwifruit, 1 pear, 30 peppermint leaves, ¼ of peeled and cored pineapple
• Directions: Process all ingredients in the juicer, shake, and serve.
• Nutrition Facts: 177 calories, 1.12 g fat, 37.01 g sugar, 3.3 g protein

If you decide to give juicing a try, let us know how you did it and how your experience was with a comment.

The post Benefits of Juicing: Is Juicing Good For You? appeared first on BuiltLean.com.

Source

Raleigh Vein and Laser Center Selected For "Best Of The Best"

Raleigh Vein and Laser Center Selected For "Best Of The Best"

Raleigh Vein and Laser Center Selected For "Best Of The Best". (PRNewsFoto/Raleigh Vein and Laser Center)

Raleigh Vein and Laser Center of Raleigh, NC has been honored with a recognition by Raleigh Metro Magazine in its selection of "Best Of The Best."

RALEIGH, N.C., July 30, 2013 /PRNewswire-USNewswire/ -- Announcing a special recognition appearing in the August, 2012 issue of Raleigh Metro Magazine published by Metro Magazine LLC. Raleigh Vein and Laser Center was selected for the following honor:

"Best Of The Best"

(Photo: http://photos.prnewswire.com/prnh/20130730/DC55660)

A spokesperson from Raleigh Vein and Laser Center commented on the recognition: "This is quite an honor for us. The fact that Raleigh Metro Magazine included Raleigh Vein and Laser Center in its selection of 'Best Of The Best,' signals that our constant efforts towards business excellence are paying off. We are proud to be included in this recognition."

About Raleigh Vein and Laser Center: a short profile by and about the honoree:

Janice Hong Messier, M.D. is a skilled vascular surgeon specializing in venous disease. Dr. Messier is board certified in general surgery, with additional board certification in vascular surgery. Dr. Messier is a Fellow of the American College of Surgeons. She is a member of the American College of Phlebology, Society of Vascular Surgery, North Carolina Medical Society and Wake County Medical Society.

Following the publication of Raleigh Vein and Laser Center's selection for Raleigh Metro Magazine's Best Of The Best list, American Registry seconded the honor and added Raleigh Vein and Laser Center to the "Registry of Business Excellence™". An exclusive recognition plaque, shown here, has been designed to commemorate this honor.

For more information on Raleigh Vein and Laser Center, located in Raleigh, NC please call 919-866-0002, or visit www.raleighvein.com.

This press release was written by American Registry, LLC with contributions from Raleigh Vein and Laser Center on behalf of Raleigh Vein and Laser Center and was distributed by PR Newswire, a subsidiary of UBM plc.

American Registry, LLC is an independent company that serves businesses and professionals such as Raleigh Vein and Laser Center who have been recognized for excellence. American Registry offers news releases, plaques and The Registry™, an online listing of over 2 million significant business and professional recognitions. Search The Registry™ at http://www.americanregistry.com.

Contact Info:

Raleigh Vein and Laser Center
Phone: 919-866-0002
Email Address: jmessier@raleighvein.com

SOURCE Raleigh Vein and Laser Center

RELATED LINKS
http://www.raleighvein.com

Source: www.prnewswire.com

Gas refineries increase blood cancer risk

Blood cancer rates appear to be higher in areas around refineries and plants that release benzene into the air and water. For complete story, click here.

Are You Suffering From Dry Eyelids?

Does the skin around your eyes feel dry and tight? Does it itch often during winter? Are there flakes, peeling, a feeling of soreness? Chances are, you may be suffering from dry skin around the eyes. You can get the whole story here.


Related Articles
http://dapiweda.blog.fc2.com/blog-entry-1.html
http://my.telegraph.co.uk/dufohole/dufohole/1/organic-skin-care-products/
http://en.netlog.com/jamieroden/blog/blogid=27191637

Zane Benefits Publishes New Information on the Washington Health...

Zane Benefits Publishes New Information on the Washington Health...

Rates Lower Than Expected for Washington Health Insurance Exchange

(PRWeb July 25, 2013)

Read the full story at http://www.prweb.com/releases/2013/7/prweb10951645.htm

Experts cautious of new HIV treatment guidelines

A leading South African AIDS expert has cautioned that new guidelines on HIV treatment may be a distraction to the country’s ongoing treatment efforts. Continue reading...

Daiichi Sankyo erweitert sein gemeinsames Arzneimittelforschungsprogramm auf Deutschland, die Schweiz und Österreich

Daiichi Sankyo erweitert sein gemeinsames Arzneimittelforschungsprogramm auf Deutschland, die Schweiz und Österreich

TOKIO, 29. Juli 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (nachfolgend Daiichi Sankyo genannt) gab am 29. Juli bekannt, dass das Unternehmen sein gemeinsames Arzneimittelforschungsprogramm „Take a New challenge for Drug diScovery (TaNeDS) Global Program", das in Zusammenarbeit mit Universitäten und Forschungsinstituten aus Japan erfolgt, auf Deutschland, die Schweiz und Österreich ausweiten wird. Im Rahmen des Programms sucht Daiichi Sankyo nach innovativen Partnern für Forschungsmaßnahmen, die zur Entdeckung neuartiger Wirkstoffkandidaten sowie neuer Arzneimittel führen könnten.

Das TaNeDS-Programm steht Forschern jeglicher Staatsangehörigkeit offen, die bei Universitäten, Forschungsinstituten und Start-up-Unternehmen in Deutschland, der Schweiz und Österreich arbeiten und in der Lage sind, in diesen Ländern an Projekten zu forschen, die den Forschungsinteressen von Daiichi Sankyo entsprechen. Hierzu zählen: neuartige biologische Wirkstoffe (Antikörper-Medikamente, etc.) zur Behandlung von Krebs, kleinmolekulare Therapeutika gegen Krebs, neuartige Arzneimitteltherapien gegen Diabetes und die Komplikationen der Diabetes-Erkrankung, neuartige Mechanismen zur Behandlung genetischer Störungen, neuartige Zielmoleküle und Verabreichungssysteme für die Nukleinsäuretherapie sowie Technologien für die Proteinkristallografie mittels Röntgenstrahlung.

Daiichi Sankyo und die U3 Pharma GmbH (mit Firmensitz im deutschen München; nachfolgend U3 Pharma genannt), eine hundertprozentige Tochtergesellschaft von Daiichi Sankyo, werden gemeinsam verschiedene Einrichtungen auswählen, die dem eigenen Forschungsbedarf entsprechen und sich im Hinblick auf die Arzneimittelforschung als originelle und vielversprechende Kandidaten mit hohem Potenzial erweisen.

Das gemeinsame Arzneimittelforschungsprojekt TaNeDS wurde im Jahr 2011 in Japan ins Leben gerufen, um mittels offener Innovation neue Forschungsbereiche aufzudecken. Zahlreiche Forscher aus Japan haben sich bei dem Programm beworben und in bestimmten Themenbereichen hat die Forschungsarbeit bereits begonnen.

Informationen zum TaNeDS Global Program
(1)	Länder, in denen Forschungsmaßnahmen durchgeführt werden: Deutschland, Schweiz und Österreich
(2)	Überblick über Forschungsprogramme Im Bereich der Technologieforschung sucht Daiichi Sankyo nach innovativen Partnern zur gemeinsamen Entdeckung neuartiger Wirkstoffe und zur Durchführung von Testprojekten, die zu neuartigen Wirkstoffkandidaten und neuen Arzneimitteln führen könnten.
(3)	Infrage kommende Forschungsprogramme
	1. Neuartige Krebstherapien mit Biologika (Antikörper-Medikamente, etc.)
	2. Neuartige kleinmolekulare Therapeutika gegen Krebs
	3. Neuartige Arzneimitteltherapien gegen Diabetes und die Komplikationen der Diabetes-Erkrankung
	4. Neuartige Mechanismen zur Behandlung genetischer Störungen
	5. Neuartige Zielmoleküle und Verabreichungssysteme für die Nukleinsäuretherapie
	6. Technologien für die Proteinkristallografie mittels Röntgenstrahlung
	Nähere Einzelheiten erhalten Sie auf der Website des TaNeDS Global Program: http://www.daiichisankyo.com/rd/taneds/index.html
(4)	Budget und Forschungszeitraum
	Bis zu 150.000 Euro jährlich für gemeinsame Forschungsprojekte mit einer maximalen Dauer von zwei Jahren.
(5)	Eignung
	Forscher jeglicher Staatsangehörigkeit, die bei Universitäten, Forschungsinstituten und Start-up-Unternehmen in Deutschland, der Schweiz und Österreich arbeiten und dazu in der Lage sind, in diesen Ländern an Projekten zu forschen, die sich mit den Forschungsinteressen von Daiichi Sankyo decken.
(6)	Auswahlprozess
	Forscher von Daiichi Sankyo und U3 Pharma werden Forschungsteams auswählen, die dem eigenen Forschungsbedarf entsprechen und sich im Hinblick auf die Arzneimittelforschung als originelle und vielversprechende Kandidaten mit hohem Potenzial erweisen.
(7)	Zeitplan
	Bewerbungsfrist: 9. September bis 1. November 2013.
	Auswahlzeitraum für die erste engere Auswahlliste: Anfang November bis Mitte Dezember 2013.
	Auswahlzeitraum für die zweite engere Auswahlliste: Mitte Dezember 2013 bis Anfang Februar 2014.
	Start der gemeinsamen Forschungsprogramme: Ab Mitte April 2014, sobald die Teams ausgewählt worden sind.

Informationen zu Daiichi Sankyo Co., Ltd.
Börsennotierung: Börsenkürzel: 4568, erster Index (First Section) der Tokioter Börse
Präsident und CEO: Joji Nakayama
Die Daiichi Sankyo Group widmet sich der Entwicklung und Bereitstellung innovativer pharmazeutischer Produkte mit hohem medizinischen Bedarf für Patienten auf entwickelten Märkten und Schwellenmärkten. Die Gruppe pflegt ihr Portfolio bereits vermarkteter Pharmazeutika zur Behandlung von Hypertonie, Hyperlipidämie und bakteriellen Infektionen, befasst sich zudem mit der Entwicklung von Therapien gegen thrombotische Störungen und konzentriert sich auf die Entdeckung neuartiger onkologischer und kardiovaskulär-metabolischer Therapien. Darüber hinaus hat die Daiichi Sankyo Group ein „Hybrid-Geschäftsmodell" geschaffen, um auf vielfältige Markt- und Kundenanforderungen zu reagieren und Wachstumschancen innerhalb der Wertschöpfungskette zu optimieren. Nähere Informationen erhalten Sie auf: www.daiichisankyo.com .

Kontakt:

Noriaki Ishida
Vorstandsmitglied und Vice President
Abteilung Unternehmenskommunikation
Daiichi Sankyo Co., Ltd.
Tel.: +81-3-6225-1126
E-Mail: kondo.toshiya.cj@daiichisankyo.co.jp
http://www.daiichisankyo.com

SOURCE Daiichi Sankyo Co., Ltd.

RELATED LINKS
http://www.daiichisankyo.com/rd/taneds/index.html
http://www.daiichisankyo.com

Source: www.prnewswire.com

Healthy Weight Loss Guide - We Promise Your Weight Loss!

Healthy Weight Loss Guide - We Promise Your Weight Loss!
The Healthy weight-loss guide presents a healthy method of losing weight. It has many important and easy-to-use general recommendations for everyday use. It is intended for healthy adults and does not take into account your ...

Theresa May diagnosed with diabetes

Theresa May diagnosed with diabetes
Home Secretary Theresa May reveals she has been diagnosed with Type 1 diabetes, but insists it will not affect her political career.

LOOK: How To Sit At Work

Get the whole story here.

Verband der Leberpatienten ELPA: EU sollte ihre Bürger besser vor Hepatitis schützen

Verband der Leberpatienten ELPA: EU sollte ihre Bürger besser vor Hepatitis schützen

BRÜSSEL, July 28, 2013 /PRNewswire/ --

Bei der Hepatitis-Prävention und dem Zugang zu medizinischer Versorgung gibt es noch immer besorgniserregende Unterschiede zwischen den Mitgliedstaaten der Europäischen Union. Fast ein Jahr nach der Veröffentlichung der Vergleichsstudie ‚Euro Hepatitis Care Index' durch den Europäischen Verband der Leberpatienten (ELPA) hat sich die Situation kaum verbessert. "Sogar die EU-Mitgliedstaaten, die ganz oben auf dem Index stehen, erbringen nicht durchwegs gute Leistungen, sondern sind in spezifischen Aspekten stark, hinken in anderen aber hinterher", sagt Tatjana Reic, Präsidentin von ELPA, anlässlich des Welt-Hepatitis-Tages (WHD) am 28. Juli.

Deutschland ist zum Beispiel gut bei Prävention und medizinischer Behandlung, zeigt jedoch Schwäche in Sachen Früherkennung. Am überraschendsten sind nach wie vor die inadäquaten Maßnahmen der Regierungen auf ganzheitlicher strategiescher Ebene. Dies und andere detailliertere Erkenntnisse über die Situation in den EU-Mitgliedstaaten, der Schweiz und in Norwegen findet man im "Euro Hepatitis Care Index", der von ELPA und der schwedischen Expertenkommission Health Consumer Powerhouse aufgestellt wurde.

"Eine Aufforderung an die Mitgliedstaaten, nationale Hepatitispläne zu entwickeln, die sich auf die alarmierenden Ungleichheiten bei Verhütung, Erkennung und den Zugang zur Behandlung viraler Hepatitis konzentrieren, ist ein wichtiger Fortschritt", sagt Frau Reic.

ELPA wurde im Jahr 2004 gegründet und repräsentiert heute 30 Leberpatientenorganisationen aus 24 Ländern. Sie beteiligt sich jedes Jahr an der Kampagne zur Förderung des WHD. Auf den diesjährigen Feierlichkeiten kündigt die WHO den Bericht Viral Hepatitis: Global Policy  (Virale Hepatitis: weltweite Richtlinien) an. Dieser Bericht enthält die Richtlinien der Regierungen der WHO-Mitgliedsstaaten für virale Hepatitis.

"Die intensiven Bemühungen der WHO, das Bewusstsein für virale Hepatitis zu steigern und die damit verbundenen Probleme anzugehen, verdient höchstes Lob. Als Patientenorganisation unterstützen wir bei ELPA diese Initiative in vollem Umfang. Indem wir dem Bericht unsere Anerkennung aussprechen und die Perspektive der Patienten weitervermitteln, hoffen wir auf eine weitere fruchtbare Zusammenarbeit mit der WHO", sagt Frau Reich.

Hepatitis ist eine Leberentzündung, die meist durch eine Virusinfektion verursacht wird. Europaweit sind 23 Millionen Bürger mit dem Hepatitisvirus infiziert und jährlich kommen viele Neuinfektionen hinzu. Erkrankungen im Zusammenhang mit Hepatitis fordern jährlich 125.000 Todesopfer und diese Zahl nimmt stetig zu. Die WHO schätzt, dass weltweit 2 Milliarden Menschen mit dem Hepatitis-B-Virus infiziert sind, ca. 150 Millionen Menschen an der chronischen Hepatitis C leiden und mehr als 350 Millionen Menschen chronische Leberinfektionen haben. Ohne Behandlung können beide Typen zu Leberzirrhose und Krebs führen und können auch schwere Folgeschäden wie Herz-Kreislauf-Krankheiten oder Diabetes verursachen.

http://www.elpa-info.org

SOURCE European Liver Patients Association (ELPA)

Source: www.prnewswire.com

Study Finds Teas to Contain High Levels of Fluoride – Could Lead to Fluoride Labels on Food

A study has recently found that some inexpensive tea bags contain concerningly-high levels of the toxic substance known as fluoride. While many health experts and governments continue to assert that fluoride is purposefully added to water supplies to protect us, some experts are now calling for fluoride levels to be stated on packages.

A study has recently found that some inexpensive tea bags contain concerningly-high levels of the toxic substance known as fluoride. While many health experts and governments continue to assert that fluoride is purposefully added to water supplies to protect us, some experts are now calling for fluoride levels to be stated on packages – a move that would greatly help those of us trying to reduce exposure to fluoride.

The study, which analyzed inexpensive tea bags from supermarkets including Asda, Sainsbury’s and Tesco, found that drinking the tea could push a person’s fluoride intake over the ‘daily recommended level’ (there should be no recommended level for a toxic substance), and put them at a higher risk of bone and dental disease. The teas provided anywhere from 75-120% of the recommended daily intake.

The DailyMail reports:

“Using Ion Selective Electrode analysis – which analyses trace elements, such as fluoride, in a liquid – of the dry tea, and of the tea infusions brewed with boiling water for two minutes, the researchers compared the fluoride levels consumed by someone drinking the average intake of four cups or a litre of tea a day.”

It is recommended that an adult does not consume more than 3-4mg of fluoride each day, but on average, a litre of inexpensive supermarket tea contained 6mg of fluoride.

Related Read: Holy Basil Removes Fluoride from Water and Supports Pineal Gland

Here are the basic results:

Dry tea

• Dry teas contained an average of 103-839 milligrams (mg) per kilogram (kg) of fluoride.

• Economy blends had the highest fluoride concentrations on average, at about 580mg per kg.

• Green teas averaged at about 397mg per kg while pure blends contained the lowest concentrations on average of 132mg per kg.

Tea Infusions

• Fluoride levels in the infusions ranged from 0.43 to 8.85g per kg overall.

• Fluoride levels differed slightly between the 2 and 10 minute infusions and the 10 and 30 minute infusions. But there was an “extremely significant” difference between the 2 and 30 minute infusions, with infusion time increasing fluoride levels.

• Economy blends (Asda Smart Price, Sainsbury’s basics, Morrisons and Tesco) contained the most fluoride, with an average of 6mg per litre in a two minute infusion.

• Pu’er and oolong tea infusions had the lowest levels of fluoride, followed by pure blends, black blends and green blends.

Why Fluoride is Dangerous

Published in the journal Food Research International, the study is a positive one in that it may actually be a stepping stone in the eventual labeling of fluoride on food products. While fluoride is touted as safe, the fluoride added to water supplies around the nation has actually been linked to heart disease, cancer, and is even known for reducing IQ. Research has even found fluoride to provide little or no benefit for teeth, which is one of its primary ‘purposes’.

You can simply type “fluoride” in the search bar here at NaturalSociety to learn more about the dangers, but also know that there are numerous ways to force fluoride out of your body. Here are 4 things to include in your fluoride detox.

Additional Sources:

Litalee

Here is the full post.

First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Gains Positive CHMP Opinion for the Treatment of COPD

First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Gains Positive CHMP Opinion for the Treatment of COPD

TOKYO, July 27, 2013 /PRNewswire/ --

• QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain positive CHMP opinion

• Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standard of care^[1]

• QVA149 demonstrated significantly reduced rates of COPD exacerbations and improved health-related quality of life compared to open-label tiotropium 18 mcg and glycopyrronium 50 mcg^[2],[3]

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information released by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro^® Breezhaler^®(indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Ultibro Breezhaler was developed under the name of QVA149.

QVA149 is an investigational fixed dose combination of two bronchodilators, indacaterol, a long-acting beta₂-adrenergic agonist (LABA) and glycopyrronium, a long-acting muscarinic antagonist (LAMA).

QVA149 significantly improved the rate of all exacerbations compared to open-label (OL) tiotropium 18 mcg, glycopyrronium 50 mcg^[3]. The rate of moderate or severe exacerbations was significantly lower compared to glycopyrronium 50 mcg and numerically lower compared to OL tiotropium 18 mcg^[2],[3].

In clinical studies, QVA149 demonstrated an acceptable safety profile with no meaningful differences between the treatment groups (placebo, indacaterol 150 mcg, glycopyrronium 50 mcg, OL tiotropium 18 mcg, SFC 50 mcg/500 mcg) in the incidence of adverse and serious adverse events^[2],[4],[5].

The European Commission generally follows the recommendations of the CHMP and normally grants a marketing authorization within three months of the opinion. Worldwide submissions and reviews of QVA149 are ongoing with US filing expected at the end of 2014.

About the IGNITE clinical trial program

In the Phase III IGNITE clinical trial program, QVA149 is being investigated for the treatment of COPD patients as an inhaled, once-daily, fixed-dose combination of indacaterol maleate and glycopyrronium bromide. IGNITE is one of the largest international clinical trial programs in COPD comprising 11 studies in total (ILLUMINATE, SHINE, BRIGHT, ENLIGHTEN, SPARK, BLAZE, ARISE, BEACON, RADIATE, LANTERN, FLAME) with more than 10,000* patients across 52 countries^[3],[6]-[17]. The first eight studies (ILLUMINATE, SHINE, BRIGHT, ENLIGHTEN, SPARK, BLAZE, ARISE, BEACON) completed in 2012. The studies were designed to investigate the efficacy, safety and tolerability, lung function, exercise endurance, exacerbations, shortness of breath and quality of life in patients treated with QVA149.

Results from five of the Phase III IGNITE trials^[3],[6]-[9]supported the CHMP's positive opinion for QVA149 which demonstrated statistically significant improvements in bronchodilation versus treatments widely used as current standards of care^[1]. Data showed that QVA149 significantly improved bronchodilation compared to OL tiotropium 18 mcg, SFC 50 mcg/500 mcg, indacaterol maleate 150 mcg, glycopyrronium 50 mcg and placebo providing a rapid onset within five minutes, and sustained bronchodilation during a 24 hour period which was maintained for up to 26 weeks, along with symptomatic improvements^{[1],[3],[7],[8]}. These symptomatic improvements included breathlessness, exercise tolerance, rescue medication use and health-related quality of life^[3]-[6].

*Total refers to all 11 IGNITE studies.

About Seebri^® Breezhaler^®

NVA237 (glycopyrronium bromide; brand name: Seebri^® Breezhaler^® (EU), Seebri^® Inhalation Capsules (Japan); ("glycopyrronium")) is a novel inhaled long-acting muscarinic antagonist (LAMA; also referred to as a long-acting anticholinergic) indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD^[18]. Glycopyrronium was exclusively licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. In Phase III studies (GLOW 1, 2 and 3) glycopyrronium demonstrated rapid improvements in lung function after first dose on Day 1 which was sustained for 24 hours and maintained over the 52 week study period compared with placebo. Glycopyrronium 50 mcg also significantly improved shortness of breath, health-related quality of life, exacerbation risk, and exercise endurance versus placebo^[19]-[21]. Glycopyrronium is approved in the EU, Japan, Switzerland, Canada, Australia and a number of other countries.

All Novartis inhaled COPD portfolio products are being developed for delivery via a single-dose dry powder inhaler (SDDPI) called the Breezhaler^® device which has low air flow resistance^[22], making it suitable for patients with airflow limitation^[23]. The Breezhaler^® device allows patients to hear, feel and see that they have taken the full dose correctly^[18].

Seebri®, Ultibro® and Breezhaler® are registered trademarks of Novartis.

About COPD

COPD is a progressive life-threatening disease that makes it hard to breathe, with symptoms that have a destructive impact on patients' function and quality of life^[24],[25]. It affects an estimated 210 million people worldwide and is projected to be the third leading cause of death by 2020^[25],[26]. COPD is often considered to be a disease of later years, but estimates suggest that 50% of those with COPD are now less than 65 years old, resulting in increases in absenteeism, premature retirement and reductions in workforce participation^[27].

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.

For further information about Sosei, please visit http://www.sosei.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Reference:

1. Vogelmeier C et al. Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes versus placebo, indacaterol, glycopyrronium, tiotropium and salmeterol/fluticasone in patients with COPD. [ATS abstract 40759; Session C45; Date: May 21, 2013 Time: 8:15 -10:45].
2. Decramer M et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. [ATS abstract 41616; Session A43; Date: May 19, 2013 Time:10:45-12:30].
3. Wedzicha JA et al. Analysis of Chronic Obstructive Pulmonary Disease Exacerbations with the Dual Bronchodilator QVA149 Compared with Glycopyrronium and Tiotropium (SPARK): a Randomized, Double-blind, Parallel-group Study. Lancet Respir Med 2013 http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(13)70052-3/abstract [Accessed 18 July 2013]
4. Welte T et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. [ATS abstract 41616; Session A43; Date: May 19, 2013, 8:15-16.30].
5. Vogelmeier C et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. [ATS abstract 41633; Session A43; Date: May 19, 2013, 8:15-16.30].
6. Beeh K et al. QVA149 once daily improves exercise tolerance and lung function in patients with COPD: the BRIGHT study. [BTS Winter Meeting 2012, Poster presentation P191; Date: 6 December; Time: 16:00-17:30].
7. Vogelmeier CF et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with COPD (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine. 2013; 1 (1): 51-60.
8. Bateman ED et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal http://erj.ersjournals.com/content/early/2013/05/30/09031936.00200212.full.pdf [Accessed 18 July 2013].
9. Dahl R, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study, Respiratory Medicine, 2013 http://dx.doi.org/10.1016/j.rmed.2013.05.016 [Accessed 19 July 2013]
10. Mahler D et al. Superior lung function with once-daily QVA149 translates into improvements in patient reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. [ATS abstract 45308; Session C20; Date: May 21, 2013 Time: 8:15-10:45].
11. ClinicalTrials.gov, November 2012. Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARISE). [Online] Available at: http://www.clinicaltrials.gov/ct2/show/NCT01285492?term=%28ARISE%29&rank=4 . [Accessed 18 July 2013].
12. ClinicalTrials.gov, n.d. Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON). [Online]
    Available at: http://www.clinicaltrials.gov/ct2/show/NCT01529632?term=BEACON&rank=6.
    [Accessed 18 July 2013].
13. ClinicalTrials.gov, n.d. Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation (RADIATE). [Online] Available at: http://www.clinicaltrials.gov/ct2/show/NCT01610037?term=GLISTEN&rank=1 .[Accessed 18 July 2013].
14. ClinicalTrials.gov, n.d. A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. [Online]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01709903?id=01709903&rank=1. [Accessed 18 July 2013].  
15. FDA Access Data, n.d.Spiriva Medical Review Part 2. [Online]
    Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-395_Spiriva.cfm. [Accessed 18 July 2013].
16. FDA Access Data, 2003.Advair Medical Review. [Online]
    Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021077_S003_ADVAIR_DISKUS.pdf. [Accessed 18 July 2013].
17. ClinicalTrial.gov, n.d. A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Futicasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD (FLAME). [Online] Available at: http://clinicaltrials.gov/ct2/show/NCT01782326?term=COPD+novartis+52&rank=2. [Accessed 18 July 2013].
18. EMA. 2012. Seebri Breezhaler EU Summary of Product Characteristics. [Online] 17 October 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002430/WC500133769.pdf. [Accessed 18 July 2013].
19. D'Urzo A et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respiratory Research 2011;12:156.
20. Kerwin E et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: The GLOW2 study. Eur Resp J 2012;40(5):1106-1114.
21. Beeh K et al. Once-daily NVA237 improves exercise endurance from first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503-513.
22. Colthorpe P et al. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long- acting muscarinic antagonist glycopyrronium. J Drug Assessment 2013;2:11-16.
23. Pavkov et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. CMRO 2010; 26; 11:2527-2533. doi:10.1185/03007995.2010.518916.
24. Joshi  M et al. Symptom burden in chronic obstructive pulmonary disease and cancer. Obstructive, occupational and environmental diseases. 2012;18(2).
25. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. [Accessed 18 July 2013].
26. Global Alliance Against Chronic Respiratory Diseases (GARD). Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Available at: http://www.who.int/gard/publications/GARD%20Book%202007.pdf. [Accessed 18 July 2013].
27. Fletcher MJ et al. COPD Uncovered: An International survey on the impact of chronic obstructive pulmonary disease (COPD) on a working age population. BMC Public Health 2011;11:612.

SOURCE Sosei Group Corporation

Source: www.prnewswire.com

Leo Beletsky: We Can Fight This Feeling: The Loss of Cory Monteith and How We Can Prevent Future Overdose Fatalities

Read the full article.

Famed hacker Barnaby Jack dies a week before hacking convention

By Jim Finkle (Reuters) - Barnaby Jack, a celebrated computer hacker who forced bank ATMs to spit out cash and sparked safety improvements in medical devices, died in San Francisco, a week before he was due to make a high-profile presentation at a hacking conference. The New Zealand-born Jack, 35, was found dead on Thursday evening by "a loved one" at an apartment in San Francisco's Nob Hill neighborhood, according to a police spokesman. He would not say what caused Jack's death but said police had ruled out foul play. ...

Read the full article.

Incentives help poor eat better

Incentives help poor eat better
A bit of extra money for buying more fruit and vegetables can help the poor eat healthier foods, US agriculture officials say.

Medicare Policies Restricting Power Wheelchair Repairs Leave Vulnerable Beneficiaries with Limited Mobility

Medicare Policies Restricting Power Wheelchair Repairs Leave Vulnerable Beneficiaries with Limited Mobility

WASHINGTON, July 26, 2013 /PRNewswire-USNewswire/ -- For years, William Welch, 58, was a truck driver, a free spirit traveling along the roads. But now Welch spends his days in a Brunswick, Md. apartment, barely able to move from a chair to the refrigerator because his Medicare-supplied power wheelchair is broken and he can't find anyone to fix it, says the American Association for Homecare (AAHomecare).

"I'm stuck in the house and I can't go anywhere," said Welch, who suffers from severe asthma and COPD. "When you lose your ability to move around, you're done. I can't see friends; I can't get groceries. I can't even get medicine for myself."

Medicare's inability to arrange repairs for beneficiaries' power wheelchairs is putting Welch's health at risk. Welch said he has fallen three times, and predicts, "I'll likely be heading to the emergency room after the next one."  

Thousands of seniors and people living with disabilities face similar health risks. Issues regarding repairs to Medicare-provided home medical equipment (HME) have persisted for years, but now they are more serious and more widespread. This dramatic escalation is the direct result of a national bidding program designed and implemented by the Centers for Medicare & Medicaid Services (CMS). The way CMS awarded contracts in the program has driven hundreds of companies out of business. Combined with perplexing rules for contract winners, the bidding program has proven itself to be a danger to the very people it is supposed to help.

For instance, Welch received his wheelchair from The SCOOTER Store several years ago. But when the company went bankrupt earlier this year, he had to call CMS for information on how to get his wheelchair repaired after it broke down in early June. He was given a list of suppliers who had won bids to provide power wheelchairs in his area.

"When I called companies on the list, they said they couldn't help me because their company didn't provide power wheelchairs," said Welch. "It turns out these companies won contracts to provide power wheelchairs, but they have no obligation to repair chairs that were provided by another company. I kept calling back Medicare, and they kept giving me the same numbers to call. It's a vicious cycle."

Welch said his only option is to pay for the repairs himself, something he can't afford. "I get a disability check because of my medical condition," he said. "Once I pay my bills I barely have enough left for food for the month. I can't pay to fix my wheelchair."

John J. Letizia, who is vice chairman of AAHomecare, explained that problems with repairs for power wheelchair provided to Medicare beneficiaries pre-date the bidding program that began two years ago in nine locations around the country.

In order to be reimbursed for repairing power wheelchairs, CMS requires companies to collect the documentation of medical necessity that was originally submitted when the beneficiary was approved to receive the equipment. That becomes a problem, Letizia said, when the supplier who provided the equipment is out of business and there is no access to the paperwork. "In those cases, CMS wants providers to go to the doctor and get the documentation from them. Good luck with that," said Letizia, who is also president of Laurel Medical Supplies, Inc. in Pennsylvania.

The bidding process adds new hurdles. For instance, only the contracted supplier who provided the power wheelchair is obligated to repair it, and that obligation only lasts through the 13-month rental period. Other bid winners in the area can fix the chair, but they aren't required to, which is why, with The SCOOTER Store out of business, Welch can't find anyone to fix his chair.

Letizia and other industry representatives met with CMS in the spring to discuss repair issues after The SCOOTER Store, formerly the nation's largest supplier of power wheelchairs, closed its doors and left thousands of Medicare beneficiaries, such as Welch, without a place to turn for repairs when their equipment breaks down.

He said the group was dissatisfied with the response from CMS. The group was told that repairs were not a problem because CMS was not auditing documentation paperwork on them. "But that could change at any time, so that wasn't a satisfactory answer," Letizia said. "Providers aren't going to start doing repairs without proper documentation, risk being audited later, and not get paid or be ordered to return payments."

So the repair situation remains unresolved, potentially leaving thousands of the most vulnerable Americans with extremely limited mobility and independence.

Major problems, like with wheelchair repairs, continue to plague the bidding program that procures HME, such as oxygen tanks, hospital beds, and diabetic testing supplies, for beneficiaries.

One of the most significant problems is that the program allows non-binding bids, which means that providers can submit unrealistically low bids that are then used to calculate the prices for products and services, but the bidders do not have to commit to signing contracts for the amounts of their bids. Yet, these bids are still used in the formula that sets prices.

Earlier this year, when CMS announced an average 45 percent price cut for most HME items and 72 percent for diabetic testing supplies, many providers were forced to lay off workers, close their businesses, or no longer service Medicare patients. In addition, Medicare beneficiaries report instances where new providers contracted under the initial stage of the bidding program were endangering their health by not providing either the equipment or the level of service they had received previously.

Lawmakers in Congress, as well as HME providers and consumer advocates, urged CMS to suspend the bidding program so that the agency could address mounting problems. Instead, CMS expanded it from nine to 91 metropolitan areas across the country on July 1. 

AAHomecare has filed a federal lawsuit asking for expansion of the program to be stopped, saying it violated its own rules by allowing companies without proper state and local licenses to submit bids and later win contracts to provide goods and services to Medicare beneficiaries. 

"It's clear that the bidding program is doing a disservice to Medicare beneficiaries," said Tyler Wilson, president of AAHomecare. "We urge Congress to take action and suspend the program until the problems are fixed. Maybe lawmakers will listen to their constituents, people like William Welch, who deserve to be treated with dignity and respect."

The American Association for Homecare represents providers of home medical or durable medical equipment and services who serve the needs of millions of Americans who require prescribed oxygen therapy, wheelchairs, enteral feeding, and other medical equipment, services, and supplies at home. Visit www.aahomecare.org.

SOURCE American Association for Homecare

RELATED LINKS
http://www.aahomecare.org

Source: www.prnewswire.com

It Work Body Wraps: The Right Way To Do It

It Work Body Wraps: The Right Way To Do It
There are two reasons why body wraps may not produce the results that you are looking for. One, you are not using the right wraps and two; you are not using them rightly. To answer ...

Health Law Boosts Status Of Alternative Medicine -- At Least On Paper

Jane Guiltinan said the husbands are usually the stubborn ones.

When her regular patients, often married women, bring their spouses to the Bastyr Center for Natural Health to try her approach to care, the men are often skeptical of the treatment plan -- a mix of herbal remedies, lifestyle changes and sometimes, conventional medicine.

Chiropractor photo by Michael Dorausch via Flickr

After 31 years of practice, Guiltinan, a naturopathic physician, said it is not uncommon for health providers without the usual nurse or doctor background to confront patients’ doubts. "I think it's a matter of education and cultural change," she said.

As for the husbands -- they often come around, Guiltinan said, but only after they see that her treatments solve their problems.

Complementary and alternative medicine -- a term that encompasses meditation, acupuncture, chiropractic care and homeopathic treatment, among other things -- has become increasingly popular. About four in 10 adults (and one in nine children) in the U.S. are using some form of alternative medicine, according to the National Institutes of Health.

And with the implementation of the Affordable Care Act, the field could make even more headway in the mainstream health care system. That is, unless the fine print -- in state legislation and insurance plans -- falls short because of unclear language and insufficient oversight.

Dr. Guiltinan

One clause of the health law in particular -- Section 2706 -- is widely discussed in the alternative medicine community because it requires that insurance companies "shall not discriminate" against any health provider with a state-recognized license. That means a licensed chiropractor treating a patient for back pain, for instance, must be reimbursed the same as medical doctors. In addition, nods to alternative medicine are threaded through other parts of the law in sections on wellness, prevention and research.  

"It's time that our health care system takes an integrative approach … whether conventional or alternative," said Sen. Tom Harkin, D-Iowa, who authored the anti-discrimination provision, in an e-mail. "Patients want good outcomes with good value, and complementary and alternative therapies can provide both."

The federal government has, in recent years, tapped providers like Guiltinan, who is also the dean at the Bastyr University College of Naturopathic Medicine, to help advise the federal government and implement legislation that could affect the way they are paid and their disciplines are incorporated into the health care continuum. In 2012, Guiltinan, based in Kenmore, Wash., was appointed to the advisory council of the National Center for Complementary and Alternative Medicine, part of the National Institutes of Health.

Proving that alternative medicine has real, measurable benefits has been key to increasing its role in the system, said John Weeks, editor of the Integrator Blog, an online publication for the alternative medicine community. The Patient-Centered Outcomes Research Institute, created by the health law, is funding studies on alternative medicine treatments to determine their effectiveness.

Weeks said both lawmakers and the general public will soon have access to that research, including the amount of money saved by integrating other forms of medicine into the current health system.

But the challenges of introducing alternative care don’t stop with science.

Because under the health care law each state defines its essential benefits plan -- what is covered by insurance -- somewhat differently, the language concerning alternative medicine has to be very specific in terms of who gets paid and for what kinds of treatment, said Deborah Senn, the former insurance commissioner in Washington and an advocate for alternative medicine coverage.

She pointed out that California excluded coverage for chiropractic care in its essential benefits plan, requiring patients to pay out of pocket for their treatment. Senn thinks the move was most likely an oversight and an unfavorable one for the profession. Four other states -- Colorado, Hawaii, Oregon and Utah -- ruled the same way in the past year.

"That's just an outright violation of the law," she said, referring to the ACA clause.

Colorado and Oregon are in the process of changing that ruling to allow chiropractic care to be covered, according to researchers at Academic Consortium for Complementary and Alternative Health Care.

Some states, like Washington, are ahead of the rest of the country in embracing alternative practitioners. The Bastyr University system, where Guiltinan works, treats 35,000 patients a year with naturopathic medicine. Sixty percent of the patients billed insurance companies for coverage.

Guiltinan said a change in the system is not only a boon for alternative medicine doctors, but helps families of all income levels access care normally limited to out-of-pocket payment. That's why some alternative medicine aficionados like Rohit Kumar are hoping the law will increase the ability of his family -- and the larger community -- to obtain this kind of care. 

Kumar, a 26-year-old business owner in Los Angeles, said his parents and brothers have always used herbs and certain foods when they get sick, and regularly see a local naturopath and herbalist. He’s only used antibiotics once, he says, when he caught dengue fever on a trip to India.

While the Kumar family pays for any treatments they need with cash -- the only payment both alternative providers accept -- they also pay for a high-deductible health plan every month to cover emergencies, like when his brother recently broke his arm falling off a bike.

Paying for a conventional health care plan and maintaining their philosophy of wellness is not cheap.

"We pay a ridiculous amount of money every month," Kumar said of the high-deductible insurance. "And none of it goes toward any type of medicine we believe in."

Even so, he said the family will continue to practice a lifestyle that values wellness achieved without a prescription -- a philosophy that Guiltinan also adopted in her practice.

As a young medical technician in a San Francisco hospital she decided that the traditional medical system was geared more toward managing diseases and symptoms rather than prevention. Naturopathic medicine, on the other hand, seemed to fit her idea of how a doctor could address the root cause of illness.

"The body has an innate ability for healing, but we get in its way," Guiltinan said. "Health is more than the absence of disease."

You can get the whole story here.

HPV raises throat cancer risk

A new analysis indicates that people infected with the human papillomavirus have an increased risk of developing esophageal cancer. You can get the whole story here.

The Basic Guidelines For Success In Weight Loss

The Basic Guidelines For Success In Weight Loss
The major problem with majority of people is that they follow an objective blindly with extremity, forgetting the very fact that moderation is the key to success. This case is best suited when pursuing weight loss objective. People bring extremity in their approach, fall hard and eventually quit.

WATCH: Living With Early-Onset Alzheimer's Disease

WATCH: Living With Early-Onset Alzheimer's Disease

Don’t Believe the Hype: UK Citizens, Farmers Don’t Want GMOs – Surveys Say

Don’t Believe the Hype: UK Citizens, Farmers Don’t Want GMOs – Surveys Say
Sources say the UK has been marketing GM foods and crops as something the majority of farmers want and as something that is at the top of priorities for everyone in the country. But, a few new surveys indicate not only do English citizens not want GM foods, but the farmers aren’t too thrilled either.

Image is actually of a protest at Zagreb,Croatia. 25th May 2013.

In the United Kingdom, there has been a growing push by the government to support genetically modified crops and the resulting foods. Sources say they’ve been marketing GM foods and crops as something the majority of farmers want and as something that is at the top of priorities for everyone in the country. But, as is the case with most modern governments, their facts seem a little hazy, particularly in light of a few new surveys that indicate not only do English citizens not want GM foods, but the farmers aren’t too thrilled either.

In England, the push for GMO support has reportedly been led by the country’s Farm Minister Owen Paterson, who GMEducation.org says has been “trumpeting” the benefits and the played-out promises of GM giants like Monsanto for the whole country to hear. Paterson’s enthusiasm looks a little misdirected, however, when it’s held up next to the findings of two surveys funded by Barclays Bank and carried out by YouGov.

Only 21% of the UK public want genetically modified foods. Approximately 70% said they would prefer to buy traditional foods rather than those that are genetically modified. Not only that, they don’t want to government acting as some publicity arm of Monsanto—43% said they were “completely against” their government promoting GM foods.

Related Read: Italy to Ban Monsanto GMO Corn with 80% Support

While the UK government would have you think the farmers in that country are “clamoring” for GM seeds, another survey indicates that simple isn’t true either. This survey, in conjunction with Farmers Weekly, found that only 47% of UK farmers think that GM technology is good.  While this survey was used by the government to show support for the GM industry, with headlines touting 61% of farmers would grow GMOs if they could, the government-sanctioned press didn’t tell the whole story.

Thirty-nine percent of those farmers surveyed said they would either not grow GM crops under any circumstances or that they would only do it if they had to. Nearly one-fourth of those surveyed swore off GM crops completely.

Even more telling, the percentage of UK farmers willing to eat genetically modified foods. Only 15% would eat GM foods. Fifty-four percent would choose conventional foods and 24% would choose organic if they could.

As with the citizens, many farmers don’t believe the government should be acting as a PR rep for the GM seed companies. About 34% said it wasn’t their place. Instead, most believe the government should be focusing on reducing food waste and educating farmers in developing countries instead.

When governments hold the best interests of corporations above the best interests of the people, there is a problem. Globally, the people don’t want their foods genetically modified and because governments and corporate interests do, there is definitely a fight to be had.

Additional Sources:

FWI